Risk factors for late cytomegalovirus infection after allogeneic stem cell transplantation using HLA-matched sibling donor: Donor lymphocyte infusion and previous history of early CMV infection

Bone Marrow Transplantation

Volumn 34, Issue 1, 2004, Pages 21-27

  Kim, D H ^a   Kim, J G ^a   Lee, N Y ^a   Sung, W J ^a   Sohn, S K ^a   Suh, J S ^a   Lee, K S ^a   Lee, K B ^a  

^a Kyungpook National University Hospital   (South Korea)

Author keywords

Allogeneic PBSCT; CMV infection; Donor lymphocyte infusion

Indexed keywords

ACICLOVIR; BUSULFAN; CIPOL N; CIPROFLOXACIN; CORTICOSTEROID DERIVATIVE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUCONAZOLE; FLUDARABINE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; METHOTREXATE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DOSE KIDNEY FUNCTION RELATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; HUMAN CYTOMEGALOVIRUS; INCIDENCE; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER VENOOCCLUSIVE DISEASE; LIVING DONOR; LOGISTIC REGRESSION ANALYSIS; LYMPHOCYTE TRANSFUSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SIBLING; STEM CELL MOBILIZATION; TREATMENT OUTCOME;

ADULT; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GANCICLOVIR; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; INCIDENCE; LYMPHOCYTE TRANSFUSION; MALE; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SIBLINGS; TIME; TRANSPLANTATION, HOMOLOGOUS;

EID: 3543074567     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704528     Document Type: Article

References (19)

1. Boeckh M, Leisenring W, Riddell SR et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003; 101: 407-414.
2. Chakrabarti S, Mackinnon S, Chopra R et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1 H in delaying immune reconstitution. Blood 2002; 99: 4357-4363.
3. Kolb HJ, Holler E. Adoptive immunotherapy with donor lymphocyte transfusions. Curr Opin Oncol 1997; 9: 139-145.
4. Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
5. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041-2050.
6. Sohn SK, Kim JG, Chae YS et al. Large-volume leukapheresis using femoral venous access for harvesting peripheral blood stem cells with the Fenwal CS 3000 Plus from normal healthy donors: predictors of CD34+ cell yield and collection efficiency. J Clin Apheresis 2003; 18: 10-15.
7. Sohn SK, Jung JT, Kim DH et al. Prophylactic growth factor-primed donor lymphocyte infusion using cells reserved at the time of transplantation after allogeneic peripheral blood stem cell transplantation in patients with high-risk hematologic malignancies. Cancer 2002; 94: 18-24.
8. Kim JG, Sohn SK, Kim DH et al. A pilot study of cytoreductive chemotherapy combined with infusion of additional peripheral blood stem cells reserved at time of harvest for transplantation in case of relapsed hematologic malignancies after allogeneic peripheral blood stem cell transplant. Bone Marrow Transplant 2003; in press.
9. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
10. Boeckh M, Bowden RA, Goodrich JM et al. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 1992; 80: 1358-1364.
11. Krause H, Hebart H, Jahn G et al. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant 1997; 19: 1111-1116.
12. Junghanss C, Storb R, Boeckh M. Risk of cytomegalovirus infection after transplantation with nonmyeloablative and reduced intensity conditioning regimens. Blood 2002; 100: 2675-2676.
13. Hakki M, Riddell SR, Storek J et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subdinical reactivation. Blood 2003; 102: 3060-3067.
14. Peggs KS, Preiser W, Kottaridis PD et al. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation. Br J Haematol 2000; 111: 782-790.
15. Boeckh M, Riddel SR, Woogerd P et al. Primary CMV infection via marrow: incidence, response to early treatment, CMV-specific immune response, and the risk of late CMV disease. 9th International Symposium on Infections in the Immunocompromised Host, Assisi, Italy, 1996.
16. Gor D, Sabin C, Prentice HG et al. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant 1998; 21: 597-605.
17. Machado CM, Menezes RX, Macedo MC et al. Extended antigenemia surveillance and late cytomegalovirus infection after allogeneic BMT. Bone Marrow Transplant 2001; 28: 1053-1059.
18. Junghanss C, Boeckh M, Carter RA et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002; 99: 1978-1985.
19. Meijer E, Dekker AW, Verdonck LF. Influence of antithymocyte globulin dose on outcome in cytomegalovirus-seropositive recipients of partially T cell-depleted stem cell grafts from matched-unrelated donors. Br J Haematol 2003; 121: 473-476.